关键词: ApoC-III Atherogenic dyslipidemia Dislipemia aterogénica Insulin resistance Resistencia a la insulina

Mesh : Animals Apolipoprotein C-III / genetics metabolism Diabetes Mellitus, Type 2 / physiopathology prevention & control Gene Expression Regulation Glucose / metabolism Humans Hypertriglyceridemia / physiopathology prevention & control Insulin / metabolism Insulin Resistance / physiology Lipoproteins, HDL / metabolism

来  源:   DOI:10.1016/j.arteri.2020.09.003

Abstract:
Apolipoprotein C-III (apoC-III) is a small protein that is predominantly synthesized in the liver and mainly resides at the surface of triglyceride-rich lipoproteins. Its expression is upregulated by glucose and reduced by insulin, with enhanced apoC-III promoting hypertriglyceridemia and inflammation in vascular cells. The protein is also elevated in patients with diabetes, suggesting that enhanced apoC-III levels might contribute to the development of type 2 diabetes mellitus. The present review focuses on the key mechanisms by which apoC-III could promote type 2 diabetes mellitus, including exacerbation of insulin resistance in skeletal muscle, activation of β-cell apoptosis, promotion of weight gain through its effects on white adipose tissue and hypothalamus, and attenuation of the beneficial effects of high-density lipoproteins on glucose metabolism. Therapeutic strategies aimed at reducing apoC-III levels may not only reduce hypertriglyceridemia but also might improve insulin resistance, thus delaying the development of type 2 diabetes mellitus.
摘要:
暂无翻译
公众号